News from us and our partners

Tags

Topics

0 results

News
4 April, 2017
Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer
News
28 March, 2017
Antoine Papiernik appointed Chairman of Sofinnova Partners
News
27 March, 2017
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
News
14 March, 2017
Sofinnova Partners announces the successful IPO of Avantium, a front runner in renewable chemistry, which raises €103 M on Euronext
News
13 March, 2017
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
News
8 March, 2017
Breath Therapeutics Raises EUR 43.5 Million in Series A Financing
News
7 March, 2017
Sofinnova Partners invests in AgroSavfe
News
7 March, 2017
Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech
News
2 March, 2017
Sofinnova Partners raises €106 million in a first closing of its Industrial Biotech Fund
News
28 February, 2017
Comet Biorefining Completes Equity Financing
News
22 February, 2017
Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis
News
22 February, 2017
Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM
News
21 February, 2017
BioAmber CEO steps down, current COO Fabrice Orecchioni named President
News
14 February, 2017
Pixium Vision receives NUB innovation reimbursement Status-1 for 150 electrode IRIS®II bionic system in Germany
News
7 February, 2017
Lysogene announces its successful IPO on Euronext Paris with nearly €22.6 m raised
News
1 February, 2017
Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain

Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer

Antoine Papiernik appointed Chairman of Sofinnova Partners

ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

Sofinnova Partners announces the successful IPO of Avantium, a front runner in renewable chemistry, which raises €103 M on Euronext

ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART

Breath Therapeutics Raises EUR 43.5 Million in Series A Financing

Sofinnova Partners invests in AgroSavfe

Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech

Sofinnova Partners raises €106 million in a first closing of its Industrial Biotech Fund

Comet Biorefining Completes Equity Financing

Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

BioAmber CEO steps down, current COO Fabrice Orecchioni named President

Pixium Vision receives NUB innovation reimbursement Status-1 for 150 electrode IRIS®II bionic system in Germany

Lysogene announces its successful IPO on Euronext Paris with nearly €22.6 m raised

Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain